Application status and prospect of botulinum toxin A in otorhinolaryngological treatment
Copyright© by the Editorial Department of Journal of Clinical Otorhinolaryngology Head and Neck Surgery..
Botulinum toxin A is a kind of neurotoxin produced by clostridium botulinum, and has been applied for nearly thirty years in China.The target of BTX-A is to selectively cleave the synaptosome-associated protein of 25 KD molecular mass, commonly abbreviated SNAP-25, thereby inhibiting neurotransmitter release and causing chemodenervation. The potential application of botulinum toxin A in treating the spasmodic dysphonia, hemifacial spasm, tinnitus, rhinitis has been confirmed both in clinical practice and previous studies. This paper is to review comprehensively the application status and the prospect of botulinum toxin A in otorhinolaryngological treatment.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
---|---|
Enthalten in: |
Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery - 34(2020), 1 vom: 09. Jan., Seite 88-91 |
Sprache: |
Chinesisch |
---|
Beteiligte Personen: |
---|
Links: |
---|
Themen: |
Botulinum Toxins, Type A |
---|
Anmerkungen: |
Date Completed 10.03.2020 Date Revised 02.11.2023 published: Print Citation Status MEDLINE |
---|
doi: |
10.13201/j.issn.1001-1781.2020.01.022 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM306797755 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM306797755 | ||
003 | DE-627 | ||
005 | 20231225124148.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||chi c | ||
024 | 7 | |a 10.13201/j.issn.1001-1781.2020.01.022 |2 doi | |
028 | 5 | 2 | |a pubmed24n1022.xml |
035 | |a (DE-627)NLM306797755 | ||
035 | |a (NLM)32086908 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a chi | ||
100 | 1 | |a Xu, Y L |e verfasserin |4 aut | |
245 | 1 | 0 | |a Application status and prospect of botulinum toxin A in otorhinolaryngological treatment |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 10.03.2020 | ||
500 | |a Date Revised 02.11.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright© by the Editorial Department of Journal of Clinical Otorhinolaryngology Head and Neck Surgery. | ||
520 | |a Botulinum toxin A is a kind of neurotoxin produced by clostridium botulinum, and has been applied for nearly thirty years in China.The target of BTX-A is to selectively cleave the synaptosome-associated protein of 25 KD molecular mass, commonly abbreviated SNAP-25, thereby inhibiting neurotransmitter release and causing chemodenervation. The potential application of botulinum toxin A in treating the spasmodic dysphonia, hemifacial spasm, tinnitus, rhinitis has been confirmed both in clinical practice and previous studies. This paper is to review comprehensively the application status and the prospect of botulinum toxin A in otorhinolaryngological treatment | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a botulinum toxin A | |
650 | 4 | |a otorhinolaryngological disease | |
650 | 4 | |a treatment | |
650 | 7 | |a Botulinum Toxins, Type A |2 NLM | |
650 | 7 | |a EC 3.4.24.69 |2 NLM | |
700 | 1 | |a Chen, J H |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery |d 2007 |g 34(2020), 1 vom: 09. Jan., Seite 88-91 |w (DE-627)NLM169708233 |x 2096-7993 |7 nnns |
773 | 1 | 8 | |g volume:34 |g year:2020 |g number:1 |g day:09 |g month:01 |g pages:88-91 |
856 | 4 | 0 | |u http://dx.doi.org/10.13201/j.issn.1001-1781.2020.01.022 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 34 |j 2020 |e 1 |b 09 |c 01 |h 88-91 |